Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 1/20 | 0.37 |
| ▸ | CACNA1B | Q00975 | 8/20 | 0.36 |
| ▸ | LTA4H | P09960 | 1/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.35 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.35 |
| ▸ | CACNA1H | O95180 | 4/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | HTR2B | P41595 | 1/20 | 0.35 |
| ▸ | GHSR | Q92847 | 1/20 | 0.34 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.34 |
| ▸ | BTK | Q06187 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL1879078 | 0.92 | SCN9A (0.41) | CCR2CACNA1BLTA4HCACNA1HHTR2C | |
| SCHEMBL1882230 | 0.91 | CYP3A4 (0.36) | LTA4HOPRM1OPRD1OPRK1HTR2C | |
| Trifluoroacetic Acid SCHEMBL1877301 | 0.90 | GHSR (0.37) | CCR2CACNA1BGHSR | |
| Trifluoroacetic Acid SCHEMBL1876380 | 0.90 | QPCT (0.34) | CCR2OPRM1OPRD1OPRK1GHSR | |
| Trifluoroacetic Acid SCHEMBL1877914 | 0.90 | PTPN2 (0.38) | CCR2CACNA1BCACNA1HHTR2CHTR2B | |
| Trifluoroacetic Acid SCHEMBL1876615 | 0.90 | PTPN2 (0.38) | CCR2CACNA1BCACNA1HHTR2CHTR2B | |
| Trifluoroacetic Acid SCHEMBL1875571 | 0.89 | PPARA (0.38) | CCR2BTK | |
| Trifluoroacetic Acid SCHEMBL1879960 | 0.89 | HDAC1 (0.39) | CACNA1BLTA4HCACNA1HHTR2CHTR2B | |
| Trifluoroacetic Acid SCHEMBL1876885 | 0.89 | HDAC1 (0.39) | CACNA1BLTA4HCACNA1HHTR2CHTR2B | |
| Trifluoroacetic Acid SCHEMBL1874802 | 0.89 | PPARG (0.32) | BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7939528-B2 | Heterocycle compounds | GLAXOSMITHKLINE LLC (US) | 2011-05-10 | — | — | US | claimed |
| US-20090054431-A1 | NOVEL HETEROCYCLE COMPOUNDS | GLAXOSMITHKLINE LLC | 2009-02-26 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054431-A1 | NOVEL HETEROCYCLE COMPOUNDS | OPRK1, OPRL1, OPRD1 | CCR2 185/4885CACNA1B 2398/4885LTA4H 677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.